dismiss

Pre-Bid now on over 2,500 items! We go LIVE on June 6th, 10AM EDT!

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

More Magazine Features

Patient Monitors – Fighting alarm fatigue, EMR integration and going wireless A look at what's new from a range of manufacturers

Technology update: Ten notable health care apps Sometimes better health care starts with pulling out your phone

Cybersecurity and device integration unlock new opportunities for HTM collaboration Don't get held hostage by ransomware

Collaboration is fueling a changing focused ultrasound landscape Researchers, clinicians, industry, government and patients all forging partnerships

Minimizing infections when reprocessing endoscopy equipment Health care facilities must maintain patient safety

See All Magazine Features  

Cardiology Homepage

Siemens and HeartIT ink deal for cardiovascular MR software Six of the 15 largest cardiac MR centers in the U.S. already use Precession

Edwards Lifesciences’ CENTERA valve demonstrates excellent clinical outcomes in new study CE mark expected in fourth quarter

Continuity of care is more important than speed in the case of chronic heart failure New research shows improved outcomes for patients returned to same hospital

The latest news in defibrillators, patient monitoring and biomedical testing equipment Devices that underscore the importance of patient safety

IBM and Sutter Health partner to predict heart failure risk using EHR data Using AI to stop cardiovascular events before they happen

Boston Scientific's S-ICD system found to have low complication rate Promising study outcome for leadless cardiac implant

Study reveals low adherence to nuclear cardiology dose reduction guidelines Most sites implemented less than half of metrics

One in five AEDs in four regions failed at least one phase of testing Five percent wouldn't even turn on at all

GE and Lantheus extend flurpiridaz F 18 agreement to 2020 Companies committed to coronary PET agent development and commercialization

U.S. and Chinese researchers work to standardize MR stroke protocols with 3-D model Better understanding ICAD with the aid of high-res imaging

GE Healthcare's Vivid iq
ultrasound system

Cardiologists sharpen their focus on preventing heart disease

by Lauren Dubinsky , Senior Reporter
From the March 2017 issue of DOTmed HealthCare Business News magazine

Highly-skilled cardiologists at hospitals and cardiac centers around the world are gradually opting for interventional techniques to treat cardiovascular diseases.

As a result, the global interventional cardiology market is expected to grow at a compound annual rate of 7 percent from 2017 to 2021, according to a recent Technavio report.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



Among the devices that caught their eye in the last year are bioresorbable stents. In July 2016, Abbott announced that it received FDA approval for its Absorb bioresorbable stent for patients with coronary artery disease.

Stent technology has evolved over the last 15 years, according to Tom Watson, senior clinical analyst at MD Buyline. The initial concept involved balloon angioplasty to open a partially blocked vessel and then placing scaffolding inside to keep it open.

After that, drug-eluting stents emerged, which held the vessel open and also provided a slow release of medication to prevent re-occlusion.

The most recent advancement in stent technology are the bioresorbable stents that dissolve after about three years. Conventional stents are made of metal, but Abbott’s Absorb is made of a naturally dissolving material.

Abbott’s thinking was if it made a stent bioresorbable, patients might not have to take the anticoagulant medications, according to Diane Robertson, director of health technology assessment at ECRI Institute.

A vessel can become irritated when a metal stent is implanted and starts to proliferate cells that build up and can close off the vessel again. Because of that, patients are required to take anticoagulant medication for at least two years.

“The question now is whether they work any better than the drug-eluting stents and whether a patient can stop taking these drugs sooner than they can with the drugeluting stents,” says Robertson.

That remains to be seen, but ECRI has conducted research to find out if the bioresorbable stent is as effective as the conventional stents. For the study, it reviewed 15 abstracts published between Jan. 1, 2010, and Feb. 4, 2016, that assessed the safety and efficacy of Absorb.

“ECRI Institute’s report found that Absorb BVS works as indicated for treating coronary artery disease, and it works as well as everolimus-eluting stents, biolimuseluting stents and bare metal stents,” says Robertson.

Robertson adds that hospitals have much to consider regarding stent technology. They need to decide whether they want to purchase the new stents, and if so, how many they want to stock as well as if they are going to continue to use the conventional stents.

[3/9/17 EDIT: Research published after this article's completion has shown patients receiving Abbott's Absorb stent may risk a higher chance of certain complications compared to patients with standard everolimus-eluting stents.

In those findings, thrombosis in the treated vessel occurred at a rate of 1.8 percent compared to 1 percent and heart attacks originating in the treated vessel also increased from 2.3 percent to 4.3 percent. Determining the pros and cons of absorbable stents is an ongoing investigation.]


TAVI coming to a hospital near you
Transcatheter aortic valve implantation was introduced about 15 years ago, and over the last decade it has grown as a therapy for higher-risk populations.

“The patient population that it’s being qualified for is gradually expanding. There are more sizes and more choices for the interventionalist to use, so that more patients can potentially be considered for this,” says MD Buyline’s Watson.

  Pages: 1 - 2 - 3 - 4 >>

Cardiology Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2017 DOTmed.com, Inc.
ALL RIGHTS RESERVED